Biologics treat psoriasis with higher efficacy and are touted with favorable safety profiles, and according to a recent review, anti-IL-12/23 and anti-IL-17A may have a better efficacy than anti-TNF-α. The review included both real-world studies on the use of biologics in pediatric psoriasis as well as findings of clinical trials focused on biologics.
Reference: Wang WM, Jin HZ. Biologics in pediatric psoriasis. J Dermatol. 2023 Jan 18. doi: 10.1111/1346-8138.16702. Epub ahead of print. PMID: 36651087.
READ MORE > https://pubmed.ncbi.nlm.nih.gov/36651087/
